Indian Firm Pulls Out Heart Drug From US Amid Cancer Risk Probes

“Test results from Hetero Labs show the amount of NDMA found in its valsartan active pharmaceutical ingredient (API) exceeds acceptable levels; although it is generally lower than the amount discovered in the API manufactured by Zhejiang,” the FDA said.

from Top Business News- News18.com https://ift.tt/2OXueSS